| Patents for A61K 47 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers, inert additives (171,128) |
|---|
| 01/21/2010 | US20100016448 Flashmelt oral dosage formulation |
| 01/21/2010 | US20100016443 Method for preparing particles comprising metal oxide coating and particles with metal oxide coating |
| 01/21/2010 | US20100016439 Ophthalmic device having therapeutic agent delivery capability and method of forming same |
| 01/21/2010 | US20100016436 Transdermal Administration of Active Agents, in Particular Diclofenac |
| 01/21/2010 | US20100016381 Stable emulsion composition |
| 01/21/2010 | US20100016225 CONJUGATES COMPRISED OF POLYMER AND HIV gp-41-DERIVED PEPTIDES AND THEIR USE IN THERAPY |
| 01/21/2010 | US20100016218 Controlled-release apoptosis modulating compositions and methods for the treatment of otic disorders |
| 01/21/2010 | US20100015723 Antagonists of Interleukin-15 |
| 01/21/2010 | US20100015671 Cyclic maltosylmaltose, cyclic maltosymaltose-forming enzyme, their preparation and uses |
| 01/21/2010 | US20100015263 Controlled release auris sensory cell modulator compositions and methods for the treatment of otic disorders |
| 01/21/2010 | US20100015253 Treatment of nail infections with no |
| 01/21/2010 | US20100015223 Crush-Resistant Tablets Intended to Prevent Accidental Misuse and Unlawful Diversion |
| 01/21/2010 | US20100015215 Use of Glycolipids as Adjuvants |
| 01/21/2010 | US20100015185 Biodegradable material based on opened starch |
| 01/21/2010 | US20100015180 Stabilizer and Vaccine Composition Comprising One or More Live Attenuated Flaviviruses |
| 01/21/2010 | US20100015172 Method to reduce the physiologic effects of drugs on mammals |
| 01/21/2010 | US20100015167 in vitro method of screening an individual for metastatic colorectal cancer cells or primary and/or metastatic stomach or esophageal cancer cells; vaccine comprising a protein that comprises human sucrase isomaltase protein |
| 01/21/2010 | US20100015166 Therapeutic antibodies |
| 01/21/2010 | US20100015165 Two Step Miniemulsion Process |
| 01/21/2010 | US20100015117 Compositions and methods for targeting a polypeptide to the central nervous system |
| 01/21/2010 | US20100015089 Heterodimeric fusion proteins useful for targeted immune therapy and general immune stimulation |
| 01/21/2010 | US20100015088 Compounds and compositions for delivering active agents |
| 01/21/2010 | US20100015054 Fluoro-substituted benzoxazole polymethine dyes |
| 01/21/2010 | US20100015050 Peg and targeting ligands on nanoparticle surface |
| 01/21/2010 | DE102008033327A1 Kieselsol-Material mit mindestens einem therapeutisch aktiven Wirkstoff zur Herstellung von biologisch degradierbaren und/oder resorbierbaren Kieselgel-Materialien für die Humanmedizin und/oder Medizintechnik Silica material with at least one therapeutically active agent for the preparation of biologically degradable and / or resorbable silica gel materials for human medicine and / or medical |
| 01/21/2010 | CA2731270A1 Method for treating atrophic age related macular degeneration |
| 01/21/2010 | CA2730996A1 Long-acting interferons and derivatives thereof and methods thereof |
| 01/21/2010 | CA2730876A1 Pharmaceutical formulation between jasmonates and its derivatives and nanocarries or microcarries |
| 01/21/2010 | CA2730806A1 Topical anesthetic for rapid local anesthesia and method of applying a topical anesthetic |
| 01/21/2010 | CA2730787A1 Topical drug delivery system |
| 01/21/2010 | CA2730745A1 Long-acting injectable analgesic formulations for animals |
| 01/21/2010 | CA2730697A1 Silica sol material having at least one therapeutically active substance for producing biologically degradable and/or resorbable silica gel materials for human medicine and/or medical technology |
| 01/21/2010 | CA2730665A1 Dosage form containing a statin |
| 01/21/2010 | CA2730534A1 Formulation for improving the bioavailability of a hydrophobic molecule |
| 01/21/2010 | CA2730498A1 Medical devices and methods for delivery of nucleic acids |
| 01/21/2010 | CA2730369A1 Compositions and methods for modulating nod-like receptor activity and uses thereof |
| 01/21/2010 | CA2730218A1 Method for manufacturing medicinal compounds containing dabigatran |
| 01/21/2010 | CA2729185A1 Functionalized polypeptides |
| 01/21/2010 | CA2727915A1 Anthracycline derivative conjugates, process for their preparation and their use as antitumor compounds |
| 01/21/2010 | CA2689472A1 Articles of manufacture releasing an active ingredient |
| 01/20/2010 | EP2145618A1 Retinoid solutions and formulations made thereform |
| 01/20/2010 | EP2144923A2 Methods of treatment using glycopegylated g-csf |
| 01/20/2010 | EP2144631A2 Multi-functional polyglutamate drug carriers |
| 01/20/2010 | EP2144625A1 A controlled release enzymatic composition and methods of use |
| 01/20/2010 | EP2144610A1 Melatonin tablet and methods of preparation and use |
| 01/20/2010 | EP2144609A2 Pharmaceutical formulations containing lipoic acid derivatives |
| 01/20/2010 | EP2144601A2 Rapidly dissolving pharmaceutical compositions comprising pullulan |
| 01/20/2010 | EP2003140B1 Galactose derivative, drug carrier and medicinal composition |
| 01/20/2010 | EP1677840B1 Methods of inhibiting the adherence of lenses to their packaging materials |
| 01/20/2010 | EP1608687B1 Novel cyclodextrin derivatives, method for the preparation thereof and use thereof for the solubilization of pharmacologically active substances |
| 01/20/2010 | EP1487493B1 Conjugates of cytotoxic agents and biologically active peptides |
| 01/20/2010 | EP1474114B1 Oral dosage form for controlled drug release |
| 01/20/2010 | EP1427396B1 Dosage forms having prolonged active ingredient release |
| 01/20/2010 | EP1418951B1 Transdermal therapeutic system (tts) with fentanyl as active ingredient |
| 01/20/2010 | EP1267880B2 Low dose entecavir formulation and use |
| 01/20/2010 | EP1028708B1 Topical compositions for prostaglandin e1 delivery |
| 01/20/2010 | CN101631569A Oligomer-antihistamine conjugates |
| 01/20/2010 | CN101631568A Oligomer-protease inhibitor conjugates |
| 01/20/2010 | CN101631567A Multi-functional drug carriers |
| 01/20/2010 | CN101631566A Polar hydrophilic prodrugs of amphetamine and other stimulants and processes for making and using the same |
| 01/20/2010 | CN101631565A Cyclodextrin formulations |
| 01/20/2010 | CN101631564A Stabilization of vitamin B12 |
| 01/20/2010 | CN101628117A Chewing soft capsule shell, chewing soft capsule drug and prepration method thereof |
| 01/20/2010 | CN100582169C Particle-stabilised emulsions |
| 01/20/2010 | CN100582130C Novel temperature and PH sensitive copolymers |
| 01/20/2010 | CN100581587C Method for comprehensively producing and utilizing nanometer biological active material |
| 01/20/2010 | CN100581561C Asiatic moonseed extract, preparations, preparing method and use thereof |
| 01/20/2010 | CN100581551C Utilization of phosphatidylserine in the treatment of attention deficit syndrome (ADHS) |
| 01/20/2010 | CN100581549C Sustained-release preparation containing hydrochlorothiazide and preparation method thereof |
| 01/20/2010 | CN100581547C Ranolazine sustained release tablets |
| 01/20/2010 | CN100581544C Injectable pharmaceutical composition for treatment and reversal of erectile dysfunction |
| 01/20/2010 | CN100581540C Isosorbide mononitrate timing quick-release and slow-release preparation |
| 01/20/2010 | CN100581538C Magnetic slow releasing diclofenac sodium preparation in supermolecular intercalation structure and its preparation method |
| 01/19/2010 | US7649023 Using polyoxyethylene glycol solutions; mixing with drug |
| 01/19/2010 | US7649022 Elastomeric polymer networks and semi-interpenetrating networks in which a linear poly(ester amide), poly(ester urethane), or poly(ester urea) polymer is crosslinked by ester or alpha-amino-acid containing cross-linkers that polymerize upon exposure to active species |
| 01/19/2010 | US7648968 Using water insoluble microparticulate glucans comprising branched beta -(1,3)(1,6) glucan, essentially free of unbranched beta -(1,3)(1,6) glucan and non-glucan components |
| 01/19/2010 | US7648962 which retain activity for stimulating cyclic guanosine monophosphate production and binding to natriuretic peptide receptor type A; improved bioavailability and half-life in circulation; for treatment of congestive heart failure |
| 01/19/2010 | US7648960 Method for delivery of monomeric or dimeric insulin complexed to diketopiperazine microparticles |
| 01/19/2010 | US7648959 Methods and compositions for the treatment of diseases of the eye |
| 01/19/2010 | US7648719 Method for oxygen treatment of unsaturated carbon compounds, novel epoxy-structured material obtained by the method, apparatus for carrying out the method and a therapeutic composition using the material |
| 01/19/2010 | US7648714 Food for skin moisture retention |
| 01/19/2010 | US7648713 Covalently crosslinked hydrogel having < equilibrium level of hydration for undergoing a volumetric expansion of >/= 50% and having a shape to occlude a lumen or void upon swelling |
| 01/19/2010 | US7648712 Fast dissolving orally consumable films containing a taste masking agent |
| 01/19/2010 | US7648711 Dimethicone-containing sustained release injection formulation |
| 01/19/2010 | US7648710 Formulation containing phosphate derivatives of electron transfer agents |
| 01/19/2010 | US7648702 Suitable for long-term storage of polypeptides containing an Fc domain of an immunoglobulin; containing polypeptide with an aggregation inhibitor selected from the group consisting of L-arginine and L-cysteine. |
| 01/19/2010 | US7648695 A halogenated xanthene derivative, preferably Rose Bengal; can be delivered at high concentrations to certain tissues |
| 01/19/2010 | CA2544422C Soft steroid compositions for use in dry powder inhalers |
| 01/19/2010 | CA2480783C An improved modified release preparation |
| 01/19/2010 | CA2464243C Method and composition for dry eye treatment |
| 01/19/2010 | CA2392361C Gastroretentive controlled release pharmaceutical dosage forms |
| 01/19/2010 | CA2183620C Sustained release composition |
| 01/15/2010 | CA2637977A1 Dosage form containing a statin |
| 01/14/2010 | WO2010006237A2 Phosphorothioate oligonucleotides non-nucleosidic phosphorothiotes as delivery agents for irna agents |
| 01/14/2010 | WO2010006236A1 Delivery of dry formulations of octreotide |
| 01/14/2010 | WO2010006200A2 Triggered release of drugs from polymer particles |
| 01/14/2010 | WO2010006194A2 Non-covalent modification of microparticles and process of preparing same |
| 01/14/2010 | WO2010005740A2 Methods for the preparation of targeting agent functionalized diblock copolymers for use in fabrication of therapeutic targeted nanoparticles |
| 01/14/2010 | WO2010005726A2 Therapeutic polymeric nanoparticles with mtor inhibitors and methods of making and using same |
| 01/14/2010 | WO2010005725A2 Therapeutic polymeric nanoparticles comprising vinca alkaloids and methods of making and using same |